{
    "clinical_study": {
        "@rank": "59",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 09, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04336254"
        },
        "id_info": {
            "org_study_id": "2020K-G005",
            "secondary_id": "hDPSC-CoVID-2019-02-2020",
            "nct_id": "NCT04336254"
        },
        "brief_title": "Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients",
        "official_title": "Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19\uff1aa Single-center, Prospective, Randomised Clinical Trial",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Renmin Hospital of Wuhan University",
                "agency_class": "Other"
            },
            "collaborator": [
                {
                    "agency": "Beijing SH Bio-Tech Corporation, Beijing (CN)",
                    "agency_class": "Other"
                },
                {
                    "agency": "Utooth Biological Technology Co., Ltd. Hubei (CN)",
                    "agency_class": "Other"
                }
            ]
        },
        "source": "Renmin Hospital of Wuhan University",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "This clinical trial is set out to evaluate the safety and efficacy of allogeneic human dental\n      pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19; to\n      explore the effects of human dental pulp mesenchymal stem cells in the treatment of severe\n      pneumonia of COVID-19 in terms of reducing mortality and improving clinical prognosis; and to\n      discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp\n      mesenchymal stem cells."
        },
        "detailed_description": {
            "textblock": "This clinical trial is set out to evaluate the followings:\n\n        1. the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the\n           treatment of severe pneumonia caused by COVID-19;\n\n        2. to explore the effects of human dental pulp mesenchymal stem cells in the treatment of\n           severe pneumonia of COVID-19 in terms of reducing mortality and improving clinical\n           prognosis; and\n\n        3. to discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp\n           mesenchymal stem cells."
        },
        "overall_status": "Recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 6, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "March 31, 2021"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "December 31, 2020"
        },
        "phase": "Phase 1/Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "Triple (Participant, Investigator, Outcomes Assessor)"
        },
        "primary_outcome": {
            "measure": "TTCI",
            "time_frame": "1-28 days",
            "description": "Time to Clinical Improvement"
        },
        "secondary_outcome": [
            {
                "measure": "Lung lesion",
                "time_frame": "1-28 days",
                "description": "Lung Lesion by CT"
            },
            {
                "measure": "Immune function",
                "time_frame": "1-28 days",
                "description": "Th1 cytokines: IL-1\u03b2, IL- 2, TNF-a, ITN-\u03b3;\nTh2 cytokines: IL- 4, IL- 6, IL- 10;\nImmunoglobulins: IgA, IgG, IgM, and total IgE;\nLymphocyte counts: CD3+, CD4+, CD8+, CD16+,CD19+, CD56+."
            },
            {
                "measure": "Time of SARS-CoV-2 clearance",
                "time_frame": "1-28 days",
                "description": "Time of SARS-CoV-2 test turns negative"
            },
            {
                "measure": "Blood test",
                "time_frame": "1-28 days",
                "description": "Blood cell count and classification"
            },
            {
                "measure": "SPO2",
                "time_frame": "1-28 days",
                "description": "Pulse oximetry"
            },
            {
                "measure": "RR",
                "time_frame": "1-28 days",
                "description": "Respiratory rate"
            },
            {
                "measure": "Body temperature",
                "time_frame": "1-28 days",
                "description": "Body temperature"
            },
            {
                "measure": "Side effects in the treatment group",
                "time_frame": "1-28 days",
                "description": "Number of the included patients with hDPSCs-related adverse events, e.g. liver or kidney function failure"
            },
            {
                "measure": "C-reactive protein (mg/L)",
                "time_frame": "1-28 days",
                "description": "C-reactive protein in microgram per litre"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "20"
        },
        "condition": "COVID-19",
        "arm_group": [
            {
                "arm_group_label": "hDPSCs group",
                "arm_group_type": "Experimental",
                "description": "Routine treatment + Intravenous injection of human dental pulp stem cells"
            },
            {
                "arm_group_label": "Control group",
                "arm_group_type": "Placebo Comparator",
                "description": "Routine treatment + Intravenous saline injection (Placebo)"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Biological",
                "intervention_name": "allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)",
                "description": "Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19",
                "arm_group_label": "hDPSCs group"
            },
            {
                "intervention_type": "Other",
                "intervention_name": "Intravenous saline injection (Placebo)",
                "description": "Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19",
                "arm_group_label": "Control group"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Aged 18-65 years;\n\n          2. Voluntarily participate in this clinical trial and sign off \"informed consent form\";\n\n          3. Diagnosed with severe pneumonia of COVID: respiratory distress, RR >30 times / min;\n             resting oxygen saturation of 93% or less; arterial partial pressure of oxygen / oxygen\n             concentration 300mmHg; SARS-CoV-2 nucleic acid test was positive.\n\n          4. Chest imaging confirm COVID-19 featured lesions in lung.\n\n        Exclusion Criteria:\n\n          1. Receive any clinical trial drug treatment for COVID-2019 within 30 days before the\n             screening assessment;\n\n          2. Severe liver disease (e.g., Child Pugh score >=C or AST> 5 times of the upper limit);\n\n          3. Patients with known severe renal insufficiency (estimated glomerular filtration rate\n             <=30mL / min/1.73 m2) or patients receiving continuous renal replacement therapy,\n             hemodialysis, peritoneal dialysis;\n\n          4. Co-infection of HIV, hepatitis B, tuberculosis, influenza virus, adenovirus or other\n             respiratory infection viruses;\n\n          5. Female patients who have no sexual protection in the last 30 days prior to the\n             screening assessment;\n\n          6. Pregnant or lactating women or women using estrogen contraception;\n\n          7. Patients who are planning to become pregnant during the study period or within 6\n             months after the end of the study period;\n\n          8. Other conditions that the researchers consider not suitable for participating in this\n             clinical trial."
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "65 Years",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Prof. Qingsong Ye, PhD,DDS",
            "role": "Study Chair",
            "affiliation": "Center for Regenerative Medicine, Renmin Hospital of Wuhan University"
        },
        "overall_contact": {
            "last_name": "Qingsong Ye, PhD,DDS",
            "phone": "+8615858242516",
            "email": "qingsongye@foxmail.com"
        },
        "overall_contact_backup": {
            "last_name": "Chenliang Zhou, PhD",
            "phone": "+862788041919",
            "phone_ext": "83920"
        },
        "location": {
            "facility": {
                "name": "Renmin Hospital of Wuhan University (East Campus)",
                "address": {
                    "city": "Wuhan",
                    "state": "Hubei",
                    "country": "China"
                }
            },
            "status": "Recruiting",
            "contact": {
                "last_name": "Chenliang Zhou, PhD",
                "phone": "+86 027 88041919",
                "phone_ext": "83920"
            }
        },
        "location_countries": {
            "country": "China"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "March 28, 2020",
        "study_first_submitted_qc": "April 3, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "April 7, 2020"
        },
        "last_update_submitted": "April 3, 2020",
        "last_update_submitted_qc": "April 3, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 7, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Principal Investigator",
            "investigator_affiliation": "Renmin Hospital of Wuhan University",
            "investigator_full_name": "Ye Qingsong",
            "investigator_title": "Professor, Director"
        },
        "keyword": [
            "Cronovirus",
            "Human Dental Pulp Stem Cells",
            "Dental Stem Cell Banking"
        ],
        "patient_data": {
            "sharing_ipd": "No"
        }
    }
}